المؤلفون: Chiyoshi Toyama, Motonari Nomura, Yuko Tazuke, Chisato Yokota, Naoki Kagawa, Haruhiko Kishima, Akihiro Yoshimura, Takeshi Ujike, Akira Nagahara, Norio Nonomura, Tateki Kubo, Futoshi Matsui, Fumi Matsumoto, Hiroomi Okuyama

المصدر: Surgical Case Reports, Vol 8, Iss 1, Pp 1-7 (2022)

مصطلحات موضوعية: Conjoined twin, Pygopagus, Anal canal, Surgery, RD1-811

الوصف: Abstract Background Pygopagus is a type of conjoined twin binding at the buttocks. Some cases of pygopagus involve the fusion of the gastrointestinal tract, urinary tract, and spinal cord. Few cases of male pygopagus have been reported; however, the prognosis after separation is unclear. Herein, we report a case of male pygopagus in which successful separation was performed with the reconstruction of the anal canal. Case presentation Twins with male pygopagus were born at 35 weeks by cesarean section. They shared a common anus, penis, and scrotum with four testes. The infants had normal defecation and urination after birth. The separation surgery was scheduled when they were 5 months. Two distinct anesthesia teams and four surgical teams (neurosurgery, pediatric urology, plastic surgery, and pediatric surgery) were involved in the multidisciplinary approach. After separating the spinal cord, we found that the anal canal and sphincter muscle complex were fused near the anal aperture, and we separated them. The fused penis and testis were separated and reconstructed using the same incisional line as the other separation, and the reconstructions of the anal canals with the sphincter muscle complex were completed. Both patients had an uneventful postoperative course. At 2 years of age, they could walk and defecate independently. In addition, they voided spontaneously without urinary incontinence at the time of 3 years and 11 months. Conclusions Separation of the spinal cord with anal canal and urethral reconstruction is important for male pygopagus patients as it allows them to preserve their independent function.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2198-7793

URL الوصول: https://doaj.org/article/467fee80e7d540f4b1b89a1d4f9c6658

المؤلفون: Hidenari Hongyo, Hiroki Higashihara, Keigo Osuga, Eiji Kashiwagi, Shinya Kosai, Keisuke Nagai, Kaishu Tanaka, Yusuke Ono, Takeshi Ujike, Motohide Uemura, Ryoichi Imamura, Norio Nonomura, Noriyuki Tomiyama

المصدر: CVIR Endovascular, Vol 3, Iss 1, Pp 1-7 (2020)

مصطلحات موضوعية: Kidney neoplasms, Angiomyolipoma, Embolization, Therapeutic, Tuberous sclerosis, Diseases of the circulatory (Cardiovascular) system, RC666-701

الوصف: Abstract Background Transcatheter arterial embolization (TAE) has been widely performed for renal angiomyolipomas (AMLs) as prophylaxis or emergency treatment. On the other hand, mammalian target of rapamycin (mTOR) inhibitors have recently been used for tuberous sclerosis (TSC)-related AMLs, and no comparison between the effectiveness of mTOR inhibitors versus prophylactic selective TAE has yet been performed. Therefore, the purpose of this study was to evaluate the efficacy of TAE for AML tumor volume reduction and predictors of tumor volume decrease over 50%, with reference to the EXIST-2 trial. Methods A total of 44 patients who underwent 48 prophylactic embolization procedures for 50 AMLs in a single institution between 2004 and 2018 were included. Indications for TAE of AMLs were tumor size ≥4 cm or aneurysm ≥5 mm in diameter on contrast-enhanced computed tomography (CECT). Microspheres, ethanol, and micro-coils were used as embolic agents. The percentage volume reduction from before TAE to the minimum volume during follow-up after TAE was calculated, and predictors for 50% volume reduction were identified by univariate and multivariate binary logistic regression analyses. Results The technical success rate was 100% (50 of 50). No severe acute complications related to the procedure were encountered. Tumor volume reduction of ≥50% was observed in 35/50 AMLs. There was a significant difference in the rate of tumor volume reduction of 50% between the presence and absence of an aneurysm ≥5 mm and between tumor diameter ≥ 70 mm and

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s42155-020-00179-2; https://doaj.org/toc/2520-8934

URL الوصول: https://doaj.org/article/98cb62b7ecf54767a1c11521fbc65143

المؤلفون: Yujiro Hayashi, Kazutoshi Fujita, Satoshi Nojima, Eisuke Tomiyama, Makoto Matsushita, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Motohide Uemura, Ryoichi Imamura, Eiichi Morii, Norio Nonomura

المصدر: Molecular Oncology, Vol 14, Iss 10, Pp 2375-2383 (2020)

مصطلحات موضوعية: bladder cancer, field change, prognosis, TERT promoter, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Telomerase reverse transcriptase (TERT) promoter mutations are frequently found in tumors or urine from patients with urothelial carcinoma (UC). TERT promoter mutations are also detected in urine from patients with no evidence of cancer but are associated with subsequent UC development. Mutations in the TERT promoter are thought to be present in nonmalignant urothelium (NMU) during early stages of tumor formation prior to pathological change, but this has not been proven directly. In this proof‐of‐concept study, we investigated the clinical utility of TERT promoter mutation analysis in NMU of patients with non‐muscle‐invasive bladder cancer (NMIBC). This single‐institute study included 53 primary tumors and 428 systematic bladder biopsy specimens from 54 patients with NMIBC. All patients underwent systematic random biopsy and transurethral resection of the bladder tumor. Genomic DNA was analyzed for TERT C228T and C250T mutations using droplet digital PCR (ddPCR). The association between TERT promoter mutation of NMU and bladder recurrence was examined by the Kaplan–Meier method and Cox proportional hazards model. Of the 54 patients, 16 (29.6%) had a TERT C228T mutation and three (5.6%) had a TERT C250T mutation in NMU. Of 428 biopsy specimens, the TERT C228T mutation was detected in 9% (31/364) of normal urothelium, 27% (4/15) of urothelial dysplasia (UD), 50% (9/18) of UD suspicious for carcinoma in situ (CIS), and 58% (18/31) of CIS. During follow‐up (median: 3.7 years), 22 (40.7%) patients experienced bladder recurrence and five (9.3%) experienced disease progression. Cox proportional hazard analysis showed that TERT C228T mutation in NMU was significantly associated with bladder recurrence after adjustment for cofounding factors (P = 0.0128). Thus, TERT C228T mutation was detected in NMU, which was a reliable independent prognostic factor of bladder tumor recurrence.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261

URL الوصول: https://doaj.org/article/f1bf8b8604af486e90a8091cd800f67f

المؤلفون: Ryo Nakamaru, Koichi Yamamoto, Satoko Nozato, Kazuhiro Hongyo, Motonori Nagasawa, Hideharu Hagiya, Futoshi Nakagami, Hiroshi Akasaka, Hitomi Kurinami, Yoichi Takami, Yasushi Takeya, Ken Sugimoto, Takeshi Ujike, Motohide Uemura, Norio Nonomura, Hiromi Rakugi

المصدر: Clinical Case Reports, Vol 7, Iss 10, Pp 1895-1899 (2019)

مصطلحات موضوعية: adrenal venous sampling, adrenalectomy, hypertension, primary aldosteronism, Medicine, Medicine (General), R5-920

الوصف: Abstract Despite being an established method to identify the unilateral subtype of primary aldosteronism with an indication of adrenalectomy, adrenal venous sampling sometimes fails primarily due to unsuccessful cannulation to adrenal veins. In such cases, the analysis of clinical findings might help to identify the indication of surgery.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2050-0904

URL الوصول: https://doaj.org/article/af0ebfa66e164ef9b59e689f4bb0591f

المؤلفون: Tetsuya Yamamoto, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Shinichiro Fukuhara, Hiroshi Kiuchi, Ryoichi Imamura, Naokazu Ibuki, Kazuma Kiyotani, Masako Kurashige, Eichi Morii, Kazutoshi Fujita, Norio Nonomura, Motohide Uemura

المصدر: Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: tuberous sclerosis complex, renal cell carcinoma, papillary renal cell carcinoma, whole-exome sequencing, cancer gene, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Tuberous sclerosis complex is a genetic disorder characterized by facial angiofibromas, intellectual disability, epilepsy, and tumor formation in multiple organs, including the kidney. Renal cell carcinoma occurs in 2%–4% of patients with tuberous sclerosis complex, often developing multiply and bilaterally. Renal cell carcinoma associated with this genetic disorder may include complex tumor heterogeneity caused by the spatially different mutational landscape. Herein, we report the case of a female patient with tuberous sclerosis complex who developed multiple renal tumors. A 44-year-old female patient with tuberous sclerosis complex developed three different histological types of tumor—angiomyolipoma, clear cell renal cell carcinoma, and papillary renal cell carcinoma—in the left kidney at first renal cell carcinoma recurrence. The papillary renal cell carcinoma was morphologically atypical, indicating that its occurrence was associated with the genetic disorder. Furthermore, whole-exome sequencing revealed distinct patterns of somatic mutation in the three tumor types, and the atypical papillary renal cell carcinoma possessed a different mutational landscape than that of typical papillary renal cell carcinomas. Our findings indicate that tumors associated with tuberous sclerosis complex may be diagnosed with careful pathological examination. Furthermore, somatic mutation profiles of these tumors revealed their unique features, providing important information for further understanding the mechanism of multiple tumor development in patients with tuberous sclerosis complex.

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.691996/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/04280d19d0c1412eab50783ffce76b4f

المؤلفون: Taigo Kato, Kazuma Kiyotani, Eisuke Tomiyama, Yoko Koh, Makoto Matsushita, Yujiro Hayashi, Kosuke Nakano, Yu Ishizuya, Cong Wang, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Kazutoshi Fujita, Norio Nonomura, Motohide Uemura

المصدر: OncoImmunology, Vol 10, Iss 1 (2021)

مصطلحات موضوعية: immune checkpoint inhibitors, predictive marker, t cell receptor, renal cell carcinoma, next-generation sequencing, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Immune checkpoint inhibitors (ICIs) offer significant clinical benefits to a subset of cancer patients via the induction of a systemic T cell-mediated anti-cancer immune response. Thus, the dynamic characterization of T cell repertoires in the peripheral blood has the potential to demonstrate noninvasive predictive biomarkers for the clinical efficacy of ICIs. In this study, we collected tumor tissues and peripheral blood samples from 25 patients with advanced kidney cancer before anti-programmed cell death protein 1 (PD-1) treatment and 1, 3, and 6 months after treatment initiation. Furthermore, we applied a next-generation sequencing approach to characterize T cell receptor (TCR) alpha and beta repertoires. TCR repertoire analysis revealed that the responders to anti-PD-1 showed an expansion of certain T cell clones even in the blood, as evidenced by the significant decrease in the TCR diversity index and increase in the number of expanded TCR clonotypes 1 month after treatment. Interestingly, these expanded TCR clonotypes in the peripheral blood were significantly shared with tumor-infiltrating T cells in responders, indicating that they have many circulating T cells that may recognize cancer antigens. Expression analysis also revealed that 1 month after treatment, T cells from the peripheral blood of responders showed significantly elevated transcriptional levels of Granzyme B, Perforin, CD39, and PD-1, markers of cancer-associated antigen-specific T cells. Altogether, we propose that global TCR repertoire analysis may allow identifying early surrogate biomarkers in the peripheral blood for predicting clinical responses to anti-PD-1 monotherapy.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2162-402X

URL الوصول: https://doaj.org/article/3a55cca753ff46178554323903ba69b8

المؤلفون: Yujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, Marie-Lisa Eich, Eisuke Tomiyama, Makoto Matsushita, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Motohide Uemura, Ryoichi Imamura, George J. Netto, Norio Nonomura

المصدر: Frontiers in Oncology, Vol 10 (2020)

مصطلحات موضوعية: bladder cancer, TERT promoter, FGFR3, cell-free DNA, liquid biopsy, UroVysion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Recent studies showed the clinical utility of next-generation sequencing of urinary cell-free DNA (cfDNA) from patients with urothelial bladder cancer (UBC). In this study, we aimed to develop urinary cfDNA analysis by droplet digital PCR (ddPCR) as a high-throughput and rapid assay for UBC detection and prognosis. We analyzed urinary cfDNA of 202 samples from 2 cohorts. Test cohort was designed for investigating clinical utility of urinary cfDNA, and was composed of 74 samples from patients with UBC, and 52 samples of benign hematuria patients. Validation cohort was designed for validation and assessment of clinical utility comparing urinary cfDNA with UroVysion (Abbott, Illinois, USA), and was composed of 40 samples from patients with UBC, and 36 prospectively collected samples from patients under surveillance after surgery for urothelial carcinoma. We performed ddPCR analysis of hotspot gene mutations (TERT promoter and FGFR3). In the test cohort, the sensitivity of urinary cfDNA diagnosis was 68.9% (51/74) and the specificity was 100% in patients with UBC. The sensitivity increased to 85.9% when used in conjunction with urine cytology. In addition, patients with high TERT C228T allele frequency (≥14%) had significantly worse prognosis in bladder tumor recurrence than patients with low TERT C228T allele frequency or negative TERT C228T (p = 0.0322). In the validation cohort, the sensitivity of urinary cfDNA was 57.5% (23/40) and the specificity was 100% in UBC patients. The sensitivity of the combination of urine cytology with our hotspot analysis (77.5%) was higher than that of urine cytology with UroVysion (68.9%). In the post-surgical surveillance group, patients positive for the TERT C228T mutation had significantly worse prognosis for bladder tumor recurrence than mutation negative patients (p < 0.001). In conclusion, ddPCR analysis of urinary cfDNA is a simple and promising assay for the clinical setting, surpassing UroVysion for detection and prognosis determination in UBC.

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2020.00755/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/1dccd974f7014f8996888db2fa8234bf

المؤلفون: Yujiro Hayashi, Atsunari Kawashima, Kazutoshi Fujita, Taigo Kato, Toyofumi Abe, Takeshi Ujike, Akira Nagahara, Shinichiro Fukuhara, Motohide Uemura, Hiroshi Kiuchi, Ryoichi Imamura, Tetsuya Saito, Koichi Toda, Yoshiki Sawa, Kentaro Kishimoto, Keigo Osuga, Norio Nonomura

المصدر: Urology Case Reports, Vol 17, Iss C, Pp 70-72 (2018)

مصطلحات موضوعية: Arterial embolization, Urethral bleeding, Left ventricular assist device, Heart failure, Diseases of the genitourinary system. Urology, RC870-923

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2214442017302942; https://doaj.org/toc/2214-4420

URL الوصول: https://doaj.org/article/439e02736e234238b0d8f4957cb51b67

المؤلفون: Eisuke Tomiyama, Kazutoshi Fujita, Maria Del Carmen Rodriguez Pena, Diana Taheri, Eri Banno, Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Motohide Uemura, Tetsuya Takao, Seiji Yamaguchi, Hiroaki Fushimi, Kazuhiro Yoshimura, Hirotsugu Uemura, George J. Netto, Norio Nonomura

المصدر: International Journal of Molecular Sciences, Vol 21, Iss 15, p 5390 (2020)

مصطلحات موضوعية: Nectin-4, Programmed Death Ligand 1, upper tract urothelial carcinoma, enfortumab vedotin, Biology (General), QH301-705.5, Chemistry, QD1-999

الوصف: Enfortumab vedotin is a novel antibody–drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma. However, the expression status of Nectin-4 in upper tract urothelial carcinoma (UTUC) remains unclear. The relationship between Nectin-4 and Programmed Death Ligand 1 (PD-L1) in UTUC is also ambiguous. We performed immunohistochemical analysis of 99 UTUC tissue microarray to assess the expression of Nectin-4 and PD-L1 in UTUC. Nectin-4-positivity was detected in 65 (65.7%) samples, and PD-L1 was detected in 24 (24.2%) samples. There was no correlation between the expression of Nectin-4 and PD-L1. Patients with strong Nectin-4-expressing tumors had a significantly higher risk of progression (p = 0.031) and cancer-specific mortality (p = 0.036). Strong Nectin-4 expression was also an independent predictor of disease progression in the high-risk group (pT3 ≤ or presence of lymphovascular invasion or lymph node metastasis) (Hazard ratio, 3.32 [95% confidence interval, 1.20–7.98; p = 0.027]). In conclusion, we demonstrated that Nectin-4 expression rate in UTUC was 65.7% and independent of PD-L1 expression. Strong Nectin-4 expression was associated with worse progression-free survival in high-risk UTUC. These findings suggested that enfortumab vedotin may be effective in a broad range of patients with UTUC, regardless of PD-L1 expression.

وصف الملف: electronic resource

Relation: https://www.mdpi.com/1422-0067/21/15/5390; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067

URL الوصول: https://doaj.org/article/e0fdff68a22e45b18de191c7bd55d0ba

المؤلفون: Kyosuke Matsuzaki, Kazutoshi Fujita, Yujiro Hayashi, Makoto Matsushita, Satoshi Nojima, Kentaro Jingushi, Taigo Kato, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Motohide Uemura, Ryoichi Imamura, Seiji Yamaguchi, Hiroaki Fushimi, Hiroshi Miyamoto, Eiichi Morii, Norio Nonomura

المصدر: PLoS ONE, Vol 13, Iss 8, p e0201256 (2018)

مصطلحات موضوعية: Medicine, Science

الوصف: Signal transducer and activator of transcription 3 (STAT3) plays a prominent role in the growth and invasion of several types of solid tumors. In this study, to assess the expression status and prognostic significance of the STAT3 pathway in upper urinary tract urothelial carcinoma (UTUC), we immunohistochemically stained for STAT3 and STAT3 pathway proteins, sphingosine-1-phosphate receptor 1 (S1PR1) and interleukin-6 (IL-6), in a tissue microarray containing 99 UTUC specimens. There were no significant associations between STAT3, S1PR1, or IL-6 expression pattern and tumor grade or pT stage. However, the patients with high STAT3 tumor had a significantly higher risk of both disease progression (p = 0.009) and cancer-specific mortality (p = 0.009), but not with tumors expressing S1PR1 or IL-6. High STAT3 expression in the nucleus was also associated with a significantly higher risk of both disease progression (p = 0.003) and cancer-specific mortality (p = 0.034). Multivariate analysis revealed that high STAT3 expression in the nucleus was significantly associated with cancer-specific survival after adjustment for pathological stage, lymph node involvement, lymphovascular invasion, and tumor grade (HR = 2.136, 95% CI = 1.009-4.767, p = 0.047). Our findings indicated that STAT3 could be a cancer-promoting factor and potentially a significant prognostic factor in UTUC.

وصف الملف: electronic resource

Relation: http://europepmc.org/articles/PMC6084864?pdf=render; https://doaj.org/toc/1932-6203

URL الوصول: https://doaj.org/article/2043383dad53423eaef8c5ce0c20caf4